Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Gains from Investment Securities: 2020-2023

  • Caribou Biosciences' Gains from Investment Securities was N/A to $170,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $26.5 million, marking a year-over-year change of. This contributed to the annual value of $170,000 for FY2023, which is 99.35% down from last year.
  • Caribou Biosciences' Gains from Investment Securities amounted to $170,000 in Q2 2023, which was down 99.35% from $26.2 million recorded in Q1 2022.
  • In the past 5 years, Caribou Biosciences' Gains from Investment Securities ranged from a high of $26.2 million in Q1 2022 and a low of $10,000 during Q4 2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $139,000 (2021), whereas its average is $6.6 million.